TCT 704: Outcomes After LAAC Using a Fluoropolymer Coated Device in Patients of Historically Underrepresented Racial and Ethnic Groups: A Sub-analysis of the HEAL-LAA Post Approval Study

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Boston Scientific Corporation; Edwards Lifesciences</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Abbott</li></ul>